Inovio Pharmaceuticals' (INO) "Market Outperform" Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Inovio Pharmaceuticals (NASDAQ:INO - Free Report) in a research note published on Friday morning,Benzinga reports. The brokerage currently has a $18.00 target price on the biopharmaceutical company's stock.

Several other research firms have also issued reports on INO. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $7.00 to $6.00 and set a "sector perform" rating for the company in a research report on Friday, November 15th. Oppenheimer reduced their price objective on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an "outperform" rating on the stock in a research note on Monday, November 18th. Finally, HC Wainwright lowered their target price on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a "neutral" rating for the company in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $12.80.

Inovio Pharmaceuticals Stock Performance

Shares of Inovio Pharmaceuticals stock traded down $0.11 during midday trading on Friday, reaching $1.98. The company had a trading volume of 970,945 shares, compared to its average volume of 1,935,549. The stock has a fifty day simple moving average of $3.49 and a 200 day simple moving average of $6.15. Inovio Pharmaceuticals has a 1-year low of $1.74 and a 1-year high of $14.75.

Institutional Trading of Inovio Pharmaceuticals

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp bought a new position in shares of Inovio Pharmaceuticals during the second quarter valued at approximately $661,000. Rhumbline Advisers raised its holdings in Inovio Pharmaceuticals by 5,943.0% in the 2nd quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company's stock worth $311,000 after purchasing an additional 37,857 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company's stock worth $255,000 after purchasing an additional 12,100 shares during the period. Cornercap Investment Counsel Inc. bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $184,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Inovio Pharmaceuticals during the second quarter valued at about $605,000. Institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.